<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend Rep</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend Rep</journal-id><journal-id journal-id-type="pmc-domain-id">4394</journal-id><journal-id journal-id-type="pmc-domain">dadr</journal-id><journal-title-group><journal-title>Drug and Alcohol Dependence Reports</journal-title></journal-title-group><issn pub-type="epub">2772-7246</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10877162</article-id><article-id pub-id-type="pmcid-ver">PMC10877162.1</article-id><article-id pub-id-type="pmcaid">10877162</article-id><article-id pub-id-type="pmcaiid">10877162</article-id><article-id pub-id-type="pmid">38380272</article-id><article-id pub-id-type="doi">10.1016/j.dadr.2024.100218</article-id><article-id pub-id-type="pii">S2772-7246(24)00002-7</article-id><article-id pub-id-type="publisher-id">100218</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Full Length Report</subject></subj-group></article-categories><title-group><article-title>County-level neonatal opioid withdrawal syndrome rates and real-world access to buprenorphine during pregnancy: An audit (&#8220;secret shopper&#8221;) study in Missouri</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Bedrick</surname><given-names initials="BS">Bronwyn S.</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">#</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Cary</surname><given-names initials="C">Caroline</given-names></name><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">#</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>O'Donnell</surname><given-names initials="C">Carly</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Marx</surname><given-names initials="C">Christine</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Friedman</surname><given-names initials="H">Hayley</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Carter</surname><given-names initials="EB">Ebony B.</given-names></name><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Raghuraman</surname><given-names initials="N">Nandini</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Stout</surname><given-names initials="MJ">Molly J.</given-names></name><xref rid="aff0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Ku</surname><given-names initials="BS">Benson S.</given-names></name><xref rid="aff0008" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Xu</surname><given-names initials="KY">Kevin Y</given-names></name><email>xukeviny@wustl.edu</email><xref rid="aff0009" ref-type="aff">i</xref><xref rid="fn1" ref-type="fn">#</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0011"><name name-style="western"><surname>Kelly</surname><given-names initials="JC">Jeannie C.</given-names></name><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">#</xref></contrib><aff id="aff0001"><label>a</label>Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD</aff><aff id="aff0002"><label>b</label>Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO</aff><aff id="aff0003"><label>c</label>Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX</aff><aff id="aff0004"><label>d</label>Department of Surgery, Washington University School of Medicine, St. Louis, MO</aff><aff id="aff0005"><label>e</label>Department of Pediatrics, Washington University School of Medicine, St. Louis, MO</aff><aff id="aff0006"><label>f</label>Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC</aff><aff id="aff0007"><label>g</label>Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI</aff><aff id="aff0008"><label>h</label>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA</aff><aff id="aff0009"><label>i</label>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>xukeviny@wustl.edu</email></corresp><fn id="fn1"><label>#</label><p id="notep0001">equal contributions.</p></fn></author-notes><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>2</month><year>2024</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">452561</issue-id><elocation-id>100218</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>24</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>02</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>20</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-21 17:25:10.820"><day>21</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0002">This secret shopper study shows that 81 of Missouri's 115 counties have no capacity for buprenorphine prescribing during pregnancy.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0003">Greater buprenorphine capacity did not correspond to decreased neonatal opioid withdrawal syndrome rates.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0004">Rurality did not significantly predict elevated rates of neonatal opioid withdrawal syndrome.</p></list-item></list></p></abstract><abstract id="abs0002"><sec><title>Background</title><p>Amid rising rates of neonatal opioid withdrawal syndrome (NOWS) worldwide and in many regions of the USA, we conducted an audit study (&#8220;secret shopper study&#8221;) to evaluate the influence of county-level buprenorphine capacity and rurality on county-level NOWS rates.</p></sec><sec><title>Methods</title><p>In 2019, up to three phone calls were made to buprenorphine prescribers in the state of Missouri (USA). County-level buprenorphine capacity was defined as the number of clinicians (across all specialties) accepting pregnant people divided by the number of births. Multivariable negative binomial regression models estimated associations between buprenorphine capacity, rurality, and county-level NOWS rates, controlling for potential confounders (i.e., poverty, unemployment, and physician shortages) that may correspond to higher rates of NOWS and lower rates of buprenorphine prescribing. Analyses were stratified using tertiles of county-level overdose rates (top, middle, and lowest 1/3 of overdose rates).</p></sec><sec><title>Results</title><p>Of 115 Missouri counties, 81(70 %) had no buprenorphine capacity, 17(15 %) were low-capacity (&lt;0.5-clinicians/1,000 births), and 17(15 %) were high-capacity (&#8805;0.5/1,000 births). The mean NOWS rate was 6.5/1,000 births. In Missouri counties with both the highest and lowest opioid overdose rates, higher buprenorphine capacity did not correspond to decreases in NOWS rates (incidence rate ratio[IRR]=1.23[95 %-confidence-interval[CI]=0.65&#8211;2.32] and IRR=1.57[1.21&#8211;2.03] respectively). Rurality did not correspond to greater NOWS burden in both Missouri counties with highest and lowest opioid overdose rates.</p></sec><sec><title>Conclusions</title><p>The vast majority of counties in Missouri have no capacity for buprenorphine prescribing during pregnancy. Rurality and lower buprenorphine capacity did not significantly predict elevated rates of NOWS.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Buprenorphine access</kwd><kwd>Rurality</kwd><kwd>Pregnancy</kwd><kwd>Neonatal opioid withdrawal</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0009">Opioid use disorder (OUD) is a major public health problem globally, evidenced by over 26 million people living with OUD worldwide in 2016 and 100,000 opioid overdose deaths occurring annually (<xref rid="bib0052" ref-type="bibr">Strang et al., 2020</xref>). Over the past two decades, the incidence of OUD in pregnant people has also risen worldwide, particularly in the United States of America (USA) and Canada (<xref rid="bib0015" ref-type="bibr">Davies et al., 2016</xref>). In the USA, rates of OUD during pregnancy have increased from approximately 1/1000 delivery hospitalizations in 2000 to over 6/1000 in 2014 (<xref rid="bib0018" ref-type="bibr">Haight et al., 2018</xref>). From 2017 to 2020, overdose mortality increased 81 % among pregnant and postpartum people in the USA (<xref rid="bib0008" ref-type="bibr">Bruzelius and Martins, 2022</xref>), as a recent comparison of pre- and post-COVID-19 data showed that overdose mortality increased more than 3-fold in pregnant and postpartum people aged 35&#8211;45 years in the USA from 2018 to 2021 (<xref rid="bib0019" ref-type="bibr">Han et al., 2023</xref>).</p><p id="para0010">Opioid exposure during pregnancy is associated with adverse maternal and fetal outcomes, including increased rates of neonatal opioid withdrawal syndrome (NOWS), a condition characterized by nervous system irritability, autonomic dysfunction, and gastrointestinal dysfunction, in neonates (<xref rid="bib0043" ref-type="bibr">Patrick et al., 2012</xref>, <xref rid="bib0044" ref-type="bibr">Patrick et al., 2020</xref>). While recent years have seen promising advances in diagnostic criteria development, clinical assessment, and non-pharmacologic (i.e., environmental and feeding interventions) and pharmacologic management (i.e., symptom-triggered dosing protocols) of NOWS (<xref rid="bib0035" ref-type="bibr">Mascarenhas et al., 2024</xref>), the prevalence of NOWS has grown in the USA, from 1.5/1000 births in 2004 (<xref rid="bib0030" ref-type="bibr">Kocherlakota, 2014</xref>) to 6.0/1000 births in 2020 (<xref rid="bib0012" ref-type="bibr">CDC, 2021</xref>). A January 2024 analysis of prenatal opioid exposure in the USA notes that while some states have experienced a decline in NOWS rates since 2017 (i.e., Massachusetts, Rhode Island, Connecticut, Vermont, Colorado), other states have seen increases in NOWS, especially in the Appalachian, Southern, Western, and Midwestern regions (<xref rid="bib0035" ref-type="bibr">Mascarenhas et al., 2024</xref>) Furthermore, prenatal opioid exposure is not only a problem in the USA but also worldwide. In England, the incidence of NOWS admissions to National Health Service neonatal units increased nearly 30 % from 2012 to 2017 (<xref rid="bib0048" ref-type="bibr">Rees et al., 2021</xref>). In Canada, national data (excluding Quebec) showed that NOWS hospitalizations have gradually increased from 3.5/1000 live births in 2010 to 6.3/1000 live births in 2020 (<xref rid="bib0009" ref-type="bibr">Canada.Ca, 2021</xref>). Elevated rates of NOWS have also been observed in studies from Western Australia throughout the 2000s and 2010s, remaining stable at 3&#8211;4/1000 live births (<xref rid="bib0029" ref-type="bibr">Kelty et al., 2022</xref>).</p><p id="para0011">Treating OUD during pregnancy with medications such as buprenorphine and methadone improves outcomes for mothers and infants compared to non-treatment, thus decreasing the likelihood and/or severity of NOWS (<xref rid="bib0027" ref-type="bibr">Jones et al., 2010</xref>, <xref rid="bib0028" ref-type="bibr">2008</xref>; <xref rid="bib0045" ref-type="bibr">Piske et al., 2021</xref>). Against the backdrop that approximately 50 % of pregnant people with OUD do not receive medications to treat OUD in the USA (<xref rid="bib0059" ref-type="bibr">Xu et al., 2023a</xref>, <xref rid="bib0060" ref-type="bibr">2023b</xref>), policymakers and physicians suggested that boosting buprenorphine uptake was a critical component for improving OUD outcomes (<xref rid="bib0050" ref-type="bibr">Sciences, 2019</xref>), particularly in suburban and rural communities thought to be most heavily impacted by OUD during earlier waves of the opioid epidemic (<xref rid="bib0020" ref-type="bibr">Hansen and Netherland, 2016</xref>). Although improvements in all maternal, fetal, and pregnancy outcomes with buprenorphine have been well-documented in clinical studies (<xref rid="bib0001" ref-type="bibr">ACOG, 2017</xref>; <xref rid="bib0027" ref-type="bibr">Jones et al., 2010</xref>), the relationship between real-world buprenorphine access, area-based characteristics, and NOWS rates remains a topic area that requires more research. Amid such uncertainties surrounding the influence of buprenorphine capacity on OUD outcomes, we conducted a &#8220;secret shopper&#8221; (audit) study, a method allowing us to gain insight into the real-world challenges of accessing buprenorphine that may be difficult to study via other methods (i.e., clinical trials, administrative data analyses) (<xref rid="bib0047" ref-type="bibr">Rankin et al., 2022</xref>).</p><p id="para0012">Our study sought to identify the number of prescribers offering buprenorphine to pregnant patients in the 115 counties of the Midwestern USA state of Missouri, where the rate of OUD diagnosis during pregnancy (2 %) is close to the USA national mean (2.7 % among pregnant people and 2 % among adults overall in the USA),(<xref rid="bib0049" ref-type="bibr">Roberts et al., 2023</xref>) Yet, Missouri has recently seen its rate of NOWS increase from 5.2/1000 births in 2017 to 7/1000 births in 2020.(<xref rid="bib0035" ref-type="bibr">Mascarenhas et al., 2024</xref>). Recent estimates suggesting that 40 % of pregnant and postpartum Missourans with OUD receive no medication to treat OUD (<xref rid="bib0049" ref-type="bibr">Roberts et al., 2023</xref>).</p><p id="para0013">By linking the availability of buprenorphine with county-level data on NOWS, we sought to investigate the relationship between the real-world challenges of accessing buprenorphine and OUD outcomes during pregnancy in Missouri. We were especially interested in the association between rurality and NOWS rates, given that rurality has historically received much attention for co-localizing with overdoses and more severe OUD outcomes (<xref rid="bib0016" ref-type="bibr">Friedman et al., 2023</xref>). Because the association of buprenorphine capacity and NOWS may be confounded by regional differences in OUD severity, our analyses sought to control for confounding variables such as overdose rates, physician shortages, and social determinants of health such as manufacturing, poverty, and unemployment.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><p id="para0014">This study was exempt from review by the Washington University institutional review board as &#8220;secret shopper&#8221; analyses are not considered human subjects research (<xref rid="bib0047" ref-type="bibr">Rankin et al., 2022</xref>).</p><sec id="sec0003"><label>2.1</label><title>Study design and analysis</title><p id="para0015">To determine county-level capacity for buprenorphine, we used our previously published retrospective cross-sectional phone audit of opioid treatment programs and buprenorphine clinicians in Missouri (<xref rid="bib0005" ref-type="bibr">Bedrick et al., 2020</xref>). Methods for the present &#8220;secret shopper&#8221; study have been previously described in detail and are also included in the eMethods (<xref rid="bib0005" ref-type="bibr">Bedrick et al., 2020</xref>). In brief, as part of the Drug Addiction Treatment Act (also known as DATA 2000), the Substance Abuse and Mental Health Services Administration (SAMHSA) maintains practice locations for physicians with buprenorphine waivers who have granted permission to be listed in the buprenorphine treatment practitioner locator, which can be used to study buprenorphine capacity (<xref rid="bib0025" ref-type="bibr">Jones and McCance-Katz, 2019</xref>; <xref rid="bib0026" ref-type="bibr">Jones et al., 2018</xref>). We thus used the SAMHSA locator to identify buprenorphine practitioners in December 2018.Subsequently, between February and April 2019, up to three phone calls were made to each practice to determine if the listed clinicians and treatment programs in the SAMHSA directory were currently accepting new pregnant patients. The practices were grouped by county to determine the total number of practices accepting pregnant patients per county from February to April 2019. County buprenorphine capacity was defined as the total number of clinicians treating pregnant patients divided by the number of county births from all available years (2014 to 2018).</p></sec><sec id="sec0004"><label>2.2</label><title>Predictor variable</title><p id="para0016">The primary predictor variable was buprenorphine capacity, categorized as 1) no capacity, 2) low capacity, or 3) high capacity. A county was defined as having no capacity if there were no clinicians (of any specialty) available to prescribe buprenorphine to pregnant individuals. Past work has shown that the mean number of buprenorphine clinicians per 1000 individuals in the U.S. is fewer than 0.5 full-time equivalents per 1000 births, suggesting less than half-time availability (<xref rid="bib0046" ref-type="bibr">Pourat et al., 2020</xref>). We thus employed a cutoff of &#8805;0.5 clinicians per 1000 births to signify counties with high buprenorphine capacity. Counties with fewer than 0.5 clinicians per 1000 births but more than zero were classified as low capacity.</p></sec><sec id="sec0005"><label>2.3</label><title>Outcome variable</title><p id="para0017">The primary outcome variable was county-level NOWS rates. The county of NOWS was assigned based on the location of any hospitalization, as opposed to the patient's residence (<xref rid="bib0044" ref-type="bibr">Patrick et al., 2020</xref>; <xref rid="bib0056" ref-type="bibr">Winkelman et al., 2018</xref>). Our data does not differentiate between transfer admissions or readmissions, but past studies have shown that NOWS identified in transfers was &lt;1 % (<xref rid="bib0042" ref-type="bibr">S. Patrick, S. et al., 2019</xref>). In our secondary analysis, we were particularly interested in how the relationship between buprenorphine access and NOWs may be influenced by rurality, given that much attention has historically been focused on increasing rates of OUD in rural areas since the start of the USA's overdose crisis. Using established methods, county rurality was operationalized as a three-level variable based on the degree of urbanization and adjacency to a metropolitan area: urban (&#8220;metro,&#8221; Rural-Urban Commuting Area Codes, RUC 1&#8211;3), versus intermediate (metro-adjacent, capturing suburban areas, RUC 4, 6, 8), versus rural (&#8220;nonmetro,&#8221; RUC 5, 7, 9) (<xref rid="bib0040" ref-type="bibr">S. Patrick, S. et al., 2019</xref>).</p><p id="para0018">Covariates in our analyses included county-level socioeconomic characteristics, with such variables selected a priori based on previous studies demonstrating links between opioid overdose or NOWS and poverty (<xref rid="bib0013" ref-type="bibr">Corr and Hollenbeak, 2017</xref>), unemployment (<xref rid="bib0022" ref-type="bibr">Hollingsworth et al., 2017</xref>; <xref rid="bib0040" ref-type="bibr">S. Patrick, S. et al., 2019</xref>), and manufacturing jobs (<xref rid="bib0040" ref-type="bibr">S. Patrick, S. et al., 2019</xref>). To capture how well health care served each county, we utilized Health Provider Shortage Area (HPSA) designations (<xref rid="bib0023" ref-type="bibr">HRSA, 2020</xref>). These designations are based on what proportion of the county and its populations are underserved in primary care or mental health,<sup>30</sup> grouped as binary variables (whole county versus partial/no shortage) (<xref rid="bib0031" ref-type="bibr">Ku and Druss, 2020</xref>).</p></sec><sec id="sec0006"><label>2.4</label><title>Data sources</title><p id="para0019">The Missouri Department of Health provided data for non-fatal and fatal overdoses from 2015 to 2019 (collected from outpatient and inpatient hospitalizations at non-federal hospitals and ambulatory centers), as well as cases of NOWS, which were determined using International Classification of Diseases (ICD-10 codes) from hospitalization or emergency room visits (ICD-10 codes, P96.1 or P04.49) (<xref rid="bib0014" ref-type="bibr">CSTE, 2019</xref>; <xref rid="bib0017" ref-type="bibr">Goyal et al., 2020</xref>; <xref rid="bib0054" ref-type="bibr">UrbanInstitute, 2018</xref>). Overdose data were accessed via the Missouri overdose dashboard, which is based on the Centers for Disease Control and Prevention (CDC)&#8217;s Drug Overdose Surveillance and Epidemiology program, capturing electronic health record information in a syndromic surveillance system based on established and publically available ICD-10 codes on the CDC website (<xref rid="bib0011" ref-type="bibr">CDC, 2020</xref>). As overdose codes were available by age and sex, the total number of fatal and nonfatal overdoses in reproductive-age women, defined as aged 15&#8211;45 years per CDC guidelines (<xref rid="bib0010" ref-type="bibr">CDC, 2014</xref>), was calculated per county. Population size for reproductive-age women in each county and number of births from 2014 to 2018 were obtained from the Missouri Department of Health and Senior Services (<xref rid="bib0036" ref-type="bibr">Missouri, 2020</xref>). Sociodemographic and economic characteristics of Missouri counties were acquired from the 2018&#8211;2019 Health Resources and Services Administration Area Health Resources Files, encompassing data on mental health and primary care shortage areas collected between 2017 and 2019 and data on economic characteristics collected from 2013 to 2017 (<xref rid="bib0023" ref-type="bibr">HRSA, 2020</xref>).</p></sec><sec id="sec0007"><label>2.5</label><title>Statistical analyses</title><p id="para0020">Univariate chi-square tests, Fisher exact tests, and analyses of variance were performed as appropriate. Multivariable negative binomial regression was performed to assess for associations between county demographics, buprenorphine capacity, and NOWS rates. We calculated variance inflation factors to check for multicollinearity, finding no significant collinearity among all covariates using a threshold of less than 2.0. Because the local severity of OUD may confound the relationship between buprenorphine capacity and NOWs, analyses were stratified by county fatal and non-fatal opioid overdose rates in women aged 15&#8211;45 years old. County overdose rates were divided into tertiles (with &#8220;tertile 1&#8243;=lowest 1/3 of overdose rates). <italic toggle="yes">P</italic> &lt;0.05 was our threshold for significance. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for all statistical analyses.</p></sec></sec><sec id="sec0008"><label>3</label><title>Results</title><sec id="sec0009"><label>3.1</label><title>Descriptive analyses</title><p id="para0021">Overall, we found 454 buprenorphine prescribers or opioid treatment program listings in the State of Missouri, corresponding to 349 unique practices. Of 126 addresses that were not initially reachable, 12 were reachable via an alternative phone number that was provided. In total, we were able to reach 235 practices, of which 128 were accepting new patients and 97 accepting specifically pregnant patients. The most common reason for practices being unreachable was that the phone call went to voicemail for all 3 phone call attempts, but other reasons included disconnected numbers, fax numbers provided in lieu of phone numbers, and wrong numbers (<xref rid="bib0005" ref-type="bibr">Bedrick et al., 2020</xref>).</p><p id="para0022">Next, we first conducted descriptive analyses after linking the addresses of buprenorphine prescribers or opioid treatment programs to their surrounding counties, showing that out of 115 counties in Missouri, 81 (70 %) had no capacity for buprenorphine treatment, 17 (15 %) had low capacity (&lt;0.5 clinicians/1000 births), and 17 (15 %) had high capacity (&gt;0.5 clinicians/1000 births). NOWS rates in Missouri ranged from 5.7 to 16.6 per 1000 births during the study period, with an average of 6.5 per 1000 births (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). Twenty-eight counties had NOWS rates in the highest quartile (&gt;8.19 cases per 1000 births) and were clustered in the Southeast region of the state (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>).<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Rate of NOWS per 1000 births in Missouri from 2014 to 2018.</p></caption><alt-text id="alt0001">Fig 1:</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>County-level NOWS per 1000 births in Missouri (2014&#8211;2018).</p></caption><alt-text id="alt0002">Fig 2:</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0023">Of the 98 counties with low or no buprenorphine capacity, 32 were rural (32.6 %), 36 were intermediate (36.8 %), and 30 were urban (30.6 %). (<xref rid="tbl0001" ref-type="table">Table 1</xref>). Of the 17 counties with high buprenorphine capacity, 8 were rural (47.1 %), 5 were intermediate (29.4 %), and 4 were urban (23.5 %). The majority (99 out of 115, 86 %) of all counties were designated as having mental health clinician shortages. Of the 16 counties with adequate mental health clinicians, the majority (88 %) were in counties with no capacity to care for pregnant people with OUD.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>County Socioeconomic Characteristics.</p></caption><alt-text id="alt0003">Table 1:</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">County Characteristic</th><th colspan="3" align="left" valign="top" rowspan="1">County Buprenorphine Capacity<hr/></th><th rowspan="2" align="left" valign="top" colspan="1">p-value</th><th colspan="3" align="left" valign="top" rowspan="1">Opioid Overdose Burden<hr/></th><th rowspan="2" align="left" valign="top" colspan="1">p-value</th></tr><tr><th valign="top" colspan="1" rowspan="1">No</th><th valign="top" colspan="1" rowspan="1">Low</th><th valign="top" colspan="1" rowspan="1">High</th><th valign="top" colspan="1" rowspan="1">Low</th><th valign="top" colspan="1" rowspan="1">Medium</th><th valign="top" colspan="1" rowspan="1">High</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Urban/Rural</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt;0.001</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.88</td></tr><tr><td valign="top" colspan="1" rowspan="1">Urban</td><td valign="top" colspan="1" rowspan="1">17 (21)</td><td valign="top" colspan="1" rowspan="1">13 (76)</td><td valign="top" colspan="1" rowspan="1">4 (24)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">12 (32)</td><td valign="top" colspan="1" rowspan="1">11 (28)</td><td valign="top" colspan="1" rowspan="1">11 (29)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Intermediate</td><td valign="top" colspan="1" rowspan="1">33 (41)</td><td valign="top" colspan="1" rowspan="1">3 (18)</td><td valign="top" colspan="1" rowspan="1">5 (29)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">11 (29)</td><td valign="top" colspan="1" rowspan="1">15 (39)</td><td valign="top" colspan="1" rowspan="1">15 (39)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Rural</td><td valign="top" colspan="1" rowspan="1">31 (38)</td><td valign="top" colspan="1" rowspan="1">1 (6)</td><td valign="top" colspan="1" rowspan="1">8 (47)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">15 (39)</td><td valign="top" colspan="1" rowspan="1">13 (33)</td><td valign="top" colspan="1" rowspan="1">12 (32)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">PCPSA</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.58</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.13</td></tr><tr><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">9 (11)</td><td valign="top" colspan="1" rowspan="1">1 (6)</td><td valign="top" colspan="1" rowspan="1">0 (0)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">6 (16)</td><td valign="top" colspan="1" rowspan="1">3 (8)</td><td valign="top" colspan="1" rowspan="1">1 (3)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">72 (89)</td><td valign="top" colspan="1" rowspan="1">16 (94)</td><td valign="top" colspan="1" rowspan="1">17 (100)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">32 (84)</td><td valign="top" colspan="1" rowspan="1">36 (15)</td><td valign="top" colspan="1" rowspan="1">6 (16)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">MHPSA</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.20</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.84</td></tr><tr><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">14 (17)</td><td valign="top" colspan="1" rowspan="1">2 (12)</td><td valign="top" colspan="1" rowspan="1">0 (0)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">4 (11)</td><td valign="top" colspan="1" rowspan="1">6 (15)</td><td valign="top" colspan="1" rowspan="1">6 (16)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">67 (83)</td><td valign="top" colspan="1" rowspan="1">15 (88)</td><td valign="top" colspan="1" rowspan="1">17 (100)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">34 (89)</td><td valign="top" colspan="1" rowspan="1">33 (85)</td><td valign="top" colspan="1" rowspan="1">32 (84)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Poverty (%)</td><td valign="top" colspan="1" rowspan="1">17<break/>(13, 20)</td><td valign="top" colspan="1" rowspan="1">15<break/>(11, 18)</td><td valign="top" colspan="1" rowspan="1">20<break/>(17, 21)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">17<break/>(13, 20)</td><td valign="top" colspan="1" rowspan="1">17<break/>(13, 20)</td><td valign="top" colspan="1" rowspan="1">17<break/>(13, 21)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Unemployment (%)</td><td valign="top" colspan="1" rowspan="1">3.3<break/>(2.9, 3.9)</td><td valign="top" colspan="1" rowspan="1">3.1<break/>(2.9, 3.6)</td><td valign="top" colspan="1" rowspan="1">3.2<break/>(3.1, 4.4)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">3.0<break/>(2.8, 3.7)</td><td valign="top" colspan="1" rowspan="1">3.1<break/>(3.0, 3.7)</td><td valign="top" colspan="1" rowspan="1">3.6<break/>(3.1, 4.4)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Manufacturing (%)</td><td valign="top" colspan="1" rowspan="1">15<break/>(11, 17)</td><td valign="top" colspan="1" rowspan="1">12<break/>(10, 14)</td><td valign="top" colspan="1" rowspan="1">14<break/>(11, 15)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">14<break/>(10, 16)</td><td valign="top" colspan="1" rowspan="1">14<break/>(10, 18)</td><td valign="top" colspan="1" rowspan="1">14<break/>(12, 17)</td><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="spara004"><p><xref rid="tbl0001" ref-type="table">Table 1</xref>: County Characteristics by buprenorphine capacity and opioid overdose burden. Categorical values are represented as n (%); Poverty, unemployment, and manufacturing rates are represented as median (Interquartile range).</p></fn><fn id="spara005"><p>PCPSA- primary care physician shortage area; MHPSA- mental health physician shortage areas.</p></fn></table-wrap-foot></table-wrap></p><p id="para0024">In terms of opioid overdose burden, 38 counties fell into the lowest tertile for fatal and nonfatal overdoses (tertile 1, &lt;2.8 cases per 1000 reproductive-age women), and 38 counties fell into the highest tertile category (tertile 3, &gt;4.0 cases per 1000 reproductive-age women). There was no statistically significant difference in rural/urban status based on opioid overdose rates, nor were counties with the highest rates of opioid overdose (tertile 3) more likely to be mental health shortage areas. However, the counties with the highest rates of opioid overdose (tertile 3) did have higher unemployment rates (<italic toggle="yes">p</italic> = 0.02) than the counties with the lowest or medium rates (tertiles 1 and 2).</p></sec><sec id="sec0010"><label>3.2</label><title>Association between buprenorphine capacity and nows rates: unadjusted and adjusted analyses</title><p id="para0025">In unadjusted analyses, we found that greater county-level capacity for buprenorphine (&#961;=0.34, <italic toggle="yes">p</italic>&lt;0.001) and higher county-level opioid overdose rates in reproductive-aged women (&#961;=0.64, <italic toggle="yes">p</italic>&lt;0.001) were associated with higher NOWS rates. We found that counties with no buprenorphine capacity had a NOWS rate of 4.99/1000 births versus 6.99/1000 vs 7.51/1000 for low and high-capacity counties. To investigate these findings further, we conducted adjusted analyses that were stratified by county-level opioid overdose rates and controlled for potential structural confounders such as poverty, employment, and access to health care. Among counties with the lowest rates of opioid overdose (tertile 1), we found that buprenorphine capacity did not correlate with a lower NOWS burden.</p><p id="para0026">Counties with low buprenorphine capacity (&lt;0.5 clinicians/1000 births) had higher NOWS rates than counties with zero buprenorphine capacity (incidence rate ratio [IRR]=2.13, 95 % confidence interval [CI]=1.26&#8211;3.59, <italic toggle="yes">p</italic> = 0.005, <xref rid="tbl0002" ref-type="table">Table 2</xref>). In contrast, counties with high buprenorphine capacity had comparable NOWS rates to counties with zero buprenorphine capacity (IRR=1.23, 95 % CI=0.65&#8211;2.32, <italic toggle="yes">p</italic> = 0.53, <xref rid="tbl0002" ref-type="table">Table 2</xref>). After stratifying by overdose rates, our adjusted analyses showed that buprenorphine capacity did not necessarily translate to a lower NOWS burden within counties with the highest rates of opioid overdose (tertile 3). For instance, counties with low buprenorphine capacity had lower NOWS rates (IRR=0.69 95 % CI=0.51&#8211;0.95, <italic toggle="yes">p</italic> = 0.02) than counties with zero buprenorphine capacity. Notably, counties with high buprenorphine capacity had higher NOWS rates than counties with zero buprenorphine capacity (IRR=1.57, 95 % CI=1.21&#8211;2.03, <italic toggle="yes">p</italic>&lt;0.001).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>County-level rates of neonatal opioid withdrawal syndrome stratified by overdose rate. Middle tertile omitted for simplicity.</p></caption><alt-text id="alt0004">Table 2:</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">Variable</th><th rowspan="2" align="left" valign="top" colspan="1">Rate of NOWS per 1000 live births</th><th colspan="2" align="left" valign="top" rowspan="1">Negative Binomial Regression Stratified by Fatal and Nonfatal Overdose Rate in Reproductive Age Women<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1">Lowest Tertile Counties<break/>IRR (95 % CI, p-value)</th><th valign="top" colspan="1" rowspan="1">Highest Tertile Counties<break/>IRR (95 % CI, p-value)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Buprenorphine Capacity</bold><xref rid="tb2fn3" ref-type="table-fn">c</xref><break/>&#8195;No capacity<break/>&#8195;Low capacity<break/>&#8195;High capacity</td><td valign="top" colspan="1" rowspan="1"><break/>4.99<break/>6.99<break/>7.51</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>2.13 (1.26, 3.59, <italic toggle="yes">p</italic> = 0.005)<break/>1.23 (0.65, 2.32, <italic toggle="yes">p</italic> = 0.53)</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>0.69 (0.51, 0.95, <italic toggle="yes">p</italic> = 0.02)<break/>1.56 (1.21, 2.03, <italic toggle="yes">p</italic>&lt;0.001)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Urban/Rural</bold><break/>&#8195;Urban<break/>&#8195;Intermediate:<break/>&#8195;Rural</td><td valign="top" colspan="1" rowspan="1"><break/>6.54<break/>5.90<break/>7.44</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>0.63 (0.29, 1.41, <italic toggle="yes">p</italic> = 0.26)<break/>1.16 (0.51, 2.66, <italic toggle="yes">p</italic> = 0.72)</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>0.81 (0.61,1.07, <italic toggle="yes">p</italic> = 0.13)<break/>0.50 (0.35, 0.73, <italic toggle="yes">p</italic>&lt;0.001)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Covariates</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Mental Health Physician Shortage Area</bold><break/>&#8195;No<break/>&#8195;Yes</td><td valign="top" colspan="1" rowspan="1"><break/><break/>4.47<break/>6.72</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>1.92 (1.05, 3.53, <italic toggle="yes">p</italic> = 0.04)</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>1.75 (1.18&#8211;2.59, <italic toggle="yes">p</italic> = 0.005)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Poverty</bold><break/>&#8195;Quartile 1<break/>&#8195;Quartile 2<break/>&#8195;Quartile 3<break/>&#8195;Quartile 4</td><td valign="top" colspan="1" rowspan="1"><break/>6.35<break/>4.45<break/>5.73<break/>11.31</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>0.77 (0.29, 2.00, <italic toggle="yes">p</italic> = 0.59)<break/>0.97 (0.57, 1.64, <italic toggle="yes">p</italic> = 0.91)<break/>2.14 (0.76, 6.01 <italic toggle="yes">p</italic> = 0.15)</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>0.91 (0.66&#8211;1.26, <italic toggle="yes">p</italic> = 0.57)<break/>0.67 (0.48&#8211;0.94, <italic toggle="yes">p</italic> = 0.02)<break/>1.49 (1.22&#8211;1.82, <italic toggle="yes">p</italic>&lt;0.001)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Unemployment</bold><break/>&#8195;Quartile 1<break/>&#8195;Quartile 2<break/>&#8195;Quartile 3<break/>&#8195;Quartile 4</td><td valign="top" colspan="1" rowspan="1"><break/>5.45<break/>6.54<break/>7.39<break/>7.34</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>0.97 (0.45, 2.06, <italic toggle="yes">p</italic> = 0.93)<break/>0.65 (0.25, 1.65, <italic toggle="yes">p</italic> = 0.36)<break/>1.67 (0.69, 4.04, <italic toggle="yes">p</italic> = 0.25)</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>1.30 (1.07, 1.58, <italic toggle="yes">p</italic> = 0.008)<break/>1.78 (1.38, 2.30, <italic toggle="yes">p</italic>&lt;0.001)<break/>1.70 (1.26, 2.29, <italic toggle="yes">p</italic>&lt;0.001)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Manufacturing</bold><xref rid="tb2fn2" ref-type="table-fn">b</xref><break/>&#8195;Quartile 1<break/>&#8195;Quartile 2<break/>&#8195;Quartile 3<break/>&#8195;Quartile 4</td><td valign="top" colspan="1" rowspan="1"><break/>6.83<break/>6.56<break/>5.35<break/>6.28</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>1.13 (0.66, 1.96, <italic toggle="yes">p</italic> = 0.65)<break/>0.64 (0.38, 1.08, <italic toggle="yes">p</italic> = 0.09)<break/>0.66 (0.30, 1.44, <italic toggle="yes">p</italic> = 0.30)</td><td valign="top" colspan="1" rowspan="1"><break/>Ref<break/>1.13 (0.96,1.34, <italic toggle="yes">p</italic> = 0.14)<break/>0.80 (0.59,1.07, <italic toggle="yes">p</italic> = 0.13)<break/>1.25 (1.06,1.49, <italic toggle="yes">p</italic> = 0.01)</td></tr></tbody></table><table-wrap-foot><fn id="spara007"><p>NOWS: neonatal opioid withdrawal syndrome; IRR: incidence rate ratio; CI: confidence interval; Ref: reference.</p></fn><fn id="spara008"><p><sup>a</sup>Overdose rate is defined as the total instances of fatal and nonfatal overdoses occurring in women 15&#8211;45 among all women aged 15&#8211;45.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn2"><label>b</label><p id="notep0006">Manufacturing is defined as the proportion of all jobs that are manufacturing.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn3"><label>c</label><p id="notep0007">Buprenorphine capacity is defined as the county's capacity to provide buprenorphine to pregnant patients. No capacity indicates no clinicians in the county prescribe buprenorphine to pregnant women; the remaining counties were divided in half based on the ratio of the number of clinicians accepting pregnant patients to the number of births.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0011"><label>3.3</label><title>Association between rurality and nows rates: unadjusted and adjusted analyses</title><p id="para0027">In unadjusted analyses, we calculated that rural counties had a NOWS rate of 7.44/1000 births versus 5.90/1000 vs 6.54/1000 for urban and intermediate counties. We subsequently conducted adjusted analyses stratifying by OUD overdose severity (tertile) and potential structural confounders. We found that among counties with lower rates of opioid overdose (tertile 1), rural status was not associated with rates of NOWS. In contrast, in counties with higher rates of overdose (tertile 3), rurality was associated with lower NOWS rate (IRR=0.50, 95 % CI=0.35&#8211;0.73, <italic toggle="yes">p</italic>&lt;0.001).</p></sec></sec><sec id="sec0012"><label>4</label><title>Discussion</title><sec id="sec0013"><label>4.1</label><title>Principal findings</title><p id="para0028">The present study shows that Missouri has an overall low capacity for buprenorphine provision during pregnancy, consistent with previous data showing a lack of accessible treatment for pregnant patients with OUD throughout the US (<xref rid="bib0059" ref-type="bibr">Xu et al., 2023a</xref>, <xref rid="bib0060" ref-type="bibr">2023b</xref>). Our study shows that Missouri counties with greater buprenorphine capacity for pregnant patients had higher rates of NOWS rather than lower rates. Our data also showed that high rates of NOWS are associated with high opioid overdose rates, which is consistent with previous studies (<xref rid="bib0055" ref-type="bibr">Villapiano et al., 2017</xref>). Recognizing that increased buprenorphine capacity may be confounded by a higher need for treatment (due to greater OUD severity), we conducted analyses stratifying by OUD overdose burden; yet, we continued to observe that buprenorphine capacity did not necessarily equate to lower NOWS rates. Past studies have highlighted the need for increased buprenorphine capacity based on local availability (<xref rid="bib0005" ref-type="bibr">Bedrick et al., 2020</xref>; <xref rid="bib0007" ref-type="bibr">Brown et al., 2018</xref>; <xref rid="bib0040" ref-type="bibr">S. Patrick, SW et al., 2019a</xref>), and our study provides a nuanced analysis of Missouri's treatment gap, suggesting that increased buprenorphine capacity is necessary but not sufficient to decrease NOWS rates in Missouri counties of greatest need. Against the backdrop of untreated and undertreated mental health conditions being common in people with OUD (<xref rid="bib0041" ref-type="bibr">Patrick et al., 2019b</xref>, <xref rid="bib61" ref-type="bibr">Xu et al., 2023c</xref>), we found that mental health care clinician shortage was strongly associated with increased rates of NOWS across all tertiles of county-level overdose burden. Interestingly, all Missouri counties with high buprenorphine capacity were designated both primary care and mental health clinician shortage areas, but 17 % of Missouri counties considered to have adequate mental health clinicians did not have any clinicians who would provide buprenorphine to pregnant patients. This may be an indicator of the siloed healthcare system, as access to mental health clinicians does not necessarily translate to OUD treatment availability or vice versa (<xref rid="bib0039" ref-type="bibr">Novak et al., 2019</xref>).</p><p id="para0029">We also sought to analyze the influence of rurality on NOWS rates. Historically, much attention surrounding the USA overdose endemic has focused on increases in drug-related poisonings and &#8220;diseases of despair&#8221; among rural and suburban people (<xref rid="bib0016" ref-type="bibr">Friedman et al., 2023</xref>). Yet, recent data has suggested that the demographics of the overdose crisis are shifting, with non-Hispanic Black women and people residing in urban areas of high Black-White segregation experiencing increasing rates of overdose (<xref rid="bib0003" ref-type="bibr">Banks et al., 2023</xref>). These trends are supported by data in these present analyses, showing that rural status did not correlate with increased NOWS burden even after controlling for socioeconomic factors and clinician presence. While this could very well represent changing trends in the overdose epidemic, it could also suggest that pregnant patients living in rural counties in Missouri with high overdose rates are traveling to other Missouri counties to give birth, resulting in lower NOWS rates in those high overdose risk rural Missouri counties. This is consistent with evidence that the majority of Missouri counties are lacking in maternity services (<xref rid="bib0037" ref-type="bibr">MoD, 2022</xref>). 47 % of Missouri counties qualify as maternity care deserts, meaning they have no obstetric clinicians and no health centers providing obstetric services, and 22.6 % of Missouri counties only have low or moderate access to these services (<xref rid="bib0039" ref-type="bibr">Novak et al., 2019</xref>). While many recent studies on OUD and NOWS have focused on the need for an increased number of clinicians in rural areas, there is still a significant need to improve access to care in urban areas, especially in Missouri counties with high OUD burden. Future studies could investigate how the distance pregnant patients must travel to receive buprenorphine and prenatal care varies by county.</p><p id="para0030">In addition, previous research has demonstrated that urban and high-risk areas have higher numbers of OUD treatment and buprenorphine clinicians (<xref rid="bib0005" ref-type="bibr">Bedrick et al., 2020</xref>). Our results suggest this increase may still be inadequate to support these areas&#8217; disproportionately high OUD burden and deflect the downstream outcome of NOWS. This highlights the critical need for continued investment of research and resources into the treatment of OUD during pregnancy in both rural and urban communities with high rates of opioid overdoses and OUD burden, even if the number of local OUD clinicians and medication to treat OUD capacity is relatively high for the state. Importantly, how pregnant patients with OUD find accepting clinicians is unknown. Even if a county had a high capacity to care for pregnant patients, if these women are unaware of these resources, this capacity is effectively diminished.</p></sec><sec id="sec0014"><label>4.2</label><title>Limitations and strengths</title><p id="para0031">With regards to limitations, first, the study is limited in that causality cannot be established from observational data. Second, measurement error from the ascertainment of diagnostic codes cannot be ruled out. Third, NOWS rates are subject to variation in case definition and may capture withdrawal from co-occurring substances beyond solely opioid-related etiologies. Fourth, our analysis does not take buprenorphine caps into consideration, and inclusion on the publically-available prescriber directories is voluntary; this may contribute to underestimation of buprenorphine capacity. Furthermore, many people may travel to other Missouri counties for treatment, which cannot be captured by our data (<xref rid="bib0033" ref-type="bibr">Markus and Pillai, 2021</xref>).</p><p id="para0032">Finally, there are several limitations that are related to generalizability. Our manuscript is focused on solely buprenorphine prescribing, as opposed to methadone. This is an important limitation, particularly in an era of increasing fentanyl contamination, because methadone may be a more effective treatment option than buprenorphine for people who experience difficulty initiating and remaining stable on buprenorphine (<xref rid="bib0051" ref-type="bibr">Silverstein et al., 2019</xref>). While shared decision-making to guide the selection of buprenorphine versus methadone is needed (<xref rid="bib0038" ref-type="bibr">Nguemeni Tiako et al., 2024</xref>), methadone can only be accessed via treatment centers, overseen by the Drug Enforcement Administration, where people are required to show up daily for supervised dosing (<xref rid="bib0058" ref-type="bibr">Work et al., 2023</xref>). The tightly-regulated methadone treatment system&#8212;where non-Hispanic Black people are overrepresented and White peers underrepresented&#8212;contrasts sharply with the more flexible framework of office-based buprenorphine treatment, which are available for general practitioners to prescribe (<xref rid="bib0002" ref-type="bibr">Andraka-Christou, 2021</xref>; <xref rid="bib0021" ref-type="bibr">Hansen and Roberts, 2012</xref>; <xref rid="bib0024" ref-type="bibr">Jackson et al., 2022</xref>). Unfortunately, the lack of racial and ethnic diversity across 112 of Missouri's 115 counties limits our ability to robustly evaluate racialized differences in county-level NOWS rates and access to buprenorphine versus methadone; however, future studies should be conducted at a more granular level (i.e., census tract, zip code) to evaluate area-based differences in NOWS rates and access to buprenorphine versus methadone</p><p id="para0033">Furthermore, our data is specific to the state of Missouri, where recent efforts to increase OUD treatment have focused on buprenorphine rather than methadone (<xref rid="bib0057" ref-type="bibr">Winograd et al., 2019</xref>). However, data has shown that &#8220;medication-first&#8221; initiatives to boost access to OUD have heavily focused on buprenorphine, suggesting that the data from Missouri is likely generalizable to many other regions of the USA (<xref rid="bib0004" ref-type="bibr">Banta-Green et al., 2022</xref>; <xref rid="bib0006" ref-type="bibr">Brady et al., 2021</xref>). Finally, while the present study was performed when the DATA 2000 X-waiver was still required, which may limit generalizability, the removal of the X-waiver has not been found to significantly increase buprenorphine prescribing rates,(<xref rid="bib0032" ref-type="bibr">Luo and Erikson, 2023</xref>; <xref rid="bib0053" ref-type="bibr">Stringfellow et al., 2023</xref>), suggesting that the lessons gained from data preceding X-waiver removal periods will likely still apply to the present.</p><p id="para0034">With regards to strengths, our study provides a detailed assessment of county-level buprenorphine capacity in relation to NOWS rates using a &#8220;secret shopper&#8221; study design, a useful method for monitoring the real-world effectiveness of health policies. Previous studies have analyzed NOWS trends based on the distance to registered medication therapy clinicians;(<xref rid="bib0007" ref-type="bibr">Brown et al., 2018</xref>; <xref rid="bib0054" ref-type="bibr">UrbanInstitute, 2018</xref>) however, our recent analysis suggest the number of registered clinicians may over-represent capacity for buprenorphine treatment, as over 40 % of clinicians could not be reached or did not accept pregnant patients (<xref rid="bib0005" ref-type="bibr">Bedrick et al., 2020</xref>). Our study used the number of clinicians who <italic toggle="yes">could</italic> be reached and who indicated they accept pregnant patients, as opposed to numbers listed on the websites of publically available directories. This methodology allowed us to analyze NOWS rates using a more accurate representation of buprenorphine capacity. Other strengths include using standardized state data and comprehensive socioeconomic demographics to further characterize counties that could benefit the most from interventions, specifically using data from reproductive-aged women to best estimate prevalence and rates. Finally, our analysis is unique by incorporating stratification of opioid overdose burden to best understand the complex relationship of a county's buprenorphine capacity and socioeconomic demographics with resultant rates of NOWS.</p></sec></sec><sec id="sec0015"><label>5</label><title>Conclusions</title><p id="para0035">In summary, we found that the vast majority of Missouri's 115 counties have no capacity for buprenorphine prescribing during pregnancy. Rurality and lower buprenorphine capacity did not significantly predict elevated rates of NOWS. Our results support the need for continued research and exploration of new predictors of OUD and NOWS risk to better target intervention strategies, as well as a need for ongoing aid to all communities struggling with OUD and its sequelae</p></sec><sec id="sec0015a"><title>CRediT authorship contribution statement</title><p id="para0035a"><bold>Bronwyn S. Bedrick:</bold> Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. <bold>Caroline Cary:</bold> Data curation, Investigation, Writing &#8211; original draft, Writing &#8211; review &amp; editing. <bold>Carly O'Donnell:</bold> Data curation, Investigation, Writing &#8211; review &amp; editing. <bold>Christine Marx:</bold> Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing &#8211; review &amp; editing. <bold>Hayley Friedman:</bold> Data curation, Investigation, Writing &#8211; review &amp; editing. <bold>Ebony B. Carter:</bold> Data curation, Investigation, Resources, Writing &#8211; review &amp; editing. <bold>Nandini Raghuraman:</bold> Data curation, Investigation, Resources, Writing &#8211; review &amp; editing. <bold>Molly J. Stout:</bold> Data curation, Investigation, Writing &#8211; review &amp; editing. <bold>Benson S. Ku:</bold> Data curation, Investigation, Methodology, Validation, Visualization, Writing &#8211; review &amp; editing. <bold>Kevin Y Xu:</bold> Data curation, Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. <bold>Jeannie C. Kelly:</bold> Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="para0047">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><mixed-citation publication-type="other" id="sbref0001">ACOG, 2017. Committee Opinion 711: opioid Use and Opioid Use Disorder in Pregnancy.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000002235</pub-id><pub-id pub-id-type="pmid">28742676</pub-id></mixed-citation></ref><ref id="bib0002"><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Andraka-Christou</surname><given-names>B.</given-names></name></person-group><article-title>Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder</article-title><source>Health Aff.</source><volume>40</volume><issue>6</issue><year>2021</year><fpage>920</fpage><lpage>927</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2020.02261</pub-id><pub-id pub-id-type="pmid">34097509</pub-id></element-citation></ref><ref id="bib0003"><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Banks</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Scroggins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paschke</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Shacham</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nance</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavazos-Rehg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Winograd</surname><given-names>R.P.</given-names></name></person-group><article-title>Examining Increasing Racial Inequities in Opioid Overdose Deaths: a Spatiotemporal Analysis of Black and White Decedents in St. Louis, Missouri, 2011-2021</article-title><source>Journal of Urban Health-Bulletin of the New York Academy of Medicine</source><volume>100</volume><issue>3</issue><year>2023</year><fpage>436</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">37221300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11524-023-00736-9</pub-id><pub-id pub-id-type="pmcid">PMC10323067</pub-id></element-citation></ref><ref id="bib0004"><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Banta-Green</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Owens</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sears</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Williams-Gilbert</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kingston</surname><given-names>S.</given-names></name></person-group><article-title>The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State</article-title><source>Addict Sci Clin Prac</source><volume>17</volume><issue>1</issue><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13722-022-00315-4</pub-id><pub-id pub-id-type="pmcid">PMC9261214</pub-id><pub-id pub-id-type="pmid">35799210</pub-id></element-citation></ref><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Bedrick</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marx</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.C.</given-names></name></person-group><article-title>Barriers to accessing opioid agonist therapy in pregnancy</article-title><source>Am J Obst Gynec Mfm</source><volume>2</volume><issue>4</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajogmf.2020.100225</pub-id><pub-id pub-id-type="pmid">33345932</pub-id></element-citation></ref><ref id="bib0006"><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Brady</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Gildersleeve</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Campos-Outcalt</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Derksen</surname><given-names>D.J.</given-names></name></person-group><article-title>Federally Qualified Health Centers Can Expand Rural Access to Buprenorphine for Opioid Use Disorder in Arizona</article-title><source>Health Serv. Insights.</source><year>2021</year><fpage>14</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/11786329211037502</pub-id><pub-id pub-id-type="pmcid">PMC8365010</pub-id><pub-id pub-id-type="pmid">34408434</pub-id></element-citation></ref><ref id="bib0007"><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Goodin</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Talbert</surname><given-names>J.C.</given-names></name></person-group><article-title>Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment</article-title><source>J. Rural. Health</source><volume>34</volume><issue>1</issue><year>2018</year><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">28685864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jrh.12251</pub-id><pub-id pub-id-type="pmcid">PMC5752583</pub-id></element-citation></ref><ref id="bib0008"><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Bruzelius</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>S.S.</given-names></name></person-group><article-title>US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020</article-title><source>JAMa</source><volume>328</volume><issue>21</issue><year>2022</year><fpage>2159</fpage><lpage>2161</lpage><pub-id pub-id-type="pmid">36472602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.17045</pub-id><pub-id pub-id-type="pmcid">PMC9856503</pub-id></element-citation></ref><ref id="bib0009"><mixed-citation publication-type="other" id="sbref0009">Canada.Ca, 2021. Neonatal abstinence syndrome in Canada: a descriptive analysis of hospitalization data.</mixed-citation></ref><ref id="bib0010"><mixed-citation publication-type="other" id="sbref0010">CDC, 2014. Mental Health Among Women of Reproductive Age.</mixed-citation></ref><ref id="bib0011"><element-citation publication-type="book" id="sbref0011"><person-group person-group-type="author"><collab>CDC</collab></person-group><part-title>Centers For Disease Control and Prevention. Drug Overdose Surveillance and Epidemiology (DOSE) System</part-title><year>2020</year><publisher-name>US Department of Health and Human Services</publisher-name><publisher-loc>Atlanta, GA</publisher-loc><comment>Access at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov//drugoverdose/nonfatal/dose/surveillance/dashboard/index.html" id="interref0002">https://www.cdc.gov//drugoverdose/nonfatal/dose/surveillance/dashboard/index.html</ext-link></element-citation></ref><ref id="bib0012"><element-citation publication-type="book" id="sbref0012"><person-group person-group-type="author"><collab>CDC</collab></person-group><part-title>Data and Statistics About Opioid Use During Pregnancy</part-title><year>2021</year><publisher-name>CDC HCUP Data</publisher-name></element-citation></ref><ref id="bib0013"><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Corr</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Hollenbeak</surname><given-names>C.S.</given-names></name></person-group><article-title>The economic burden of neonatal abstinence syndrome in the United States</article-title><source>Addiction</source><volume>112</volume><issue>9</issue><year>2017</year><fpage>1590</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">28612362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.13842</pub-id></element-citation></ref><ref id="bib0014"><mixed-citation publication-type="other" id="sbref0014">CSTE, 2019. Council of State and Territorial Epidemiologists (CSTE) Neonatal Abstinence Syndrome Standardized Case Definition. Accessed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/2019ps/19-MCH-01_NAS_updated_5.7.19.pdf" id="interref0003">https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/2019ps/19-MCH-01_NAS_updated_5.7.19.pdf</ext-link>.</mixed-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nazareth</surname><given-names>I.</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guttmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez-Izquierdo</surname><given-names>A.</given-names></name></person-group><article-title>Neonatal drug withdrawal syndrome: cross-country comparison using hospital administrative data in England, the USA, Western Australia and Ontario</article-title><source>Canada. Arch Dis Child Fetal Neonatal Ed</source><volume>101</volume><issue>1</issue><year>2016</year><fpage>F26</fpage><lpage>F30</lpage><pub-id pub-id-type="pmid">26290479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/archdischild-2015-308948</pub-id></element-citation></ref><ref id="bib0016"><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gone</surname><given-names>J.P.</given-names></name></person-group><article-title>Deaths of despair and Indigenous data genocide</article-title><source>Lancet</source><volume>401</volume><issue>10379</issue><year>2023</year><fpage>874</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">36709769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)02404-7</pub-id></element-citation></ref><ref id="bib0017"><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Goyal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Fillo</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Manning</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Shapiro-Mendoza</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coy</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>McDow</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Keaton</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sinatra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alpren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barfield</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Diop</surname><given-names>H.</given-names></name></person-group><article-title>Identification of Substance-Exposed Newborns and Neonatal Abstinence Syndrome Using ICD-10-CM-15 Hospitals, Massachusetts, 2017</article-title><source>Mmwr-Morbid Mortal W</source><volume>69</volume><issue>29</issue><year>2020</year><fpage>951</fpage><lpage>955</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6929a2</pub-id><pub-id pub-id-type="pmcid">PMC7377822</pub-id><pub-id pub-id-type="pmid">32701936</pub-id></element-citation></ref><ref id="bib0018"><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Haight</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>Bohm</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Callaghan</surname><given-names>W.M.</given-names></name></person-group><article-title>Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014</article-title><source>MMWR. Morb. Mortal. Wkly. Rep.</source><volume>67</volume><issue>31</issue><year>2018</year><fpage>845</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">30091969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6731a1</pub-id><pub-id pub-id-type="pmcid">PMC6089335</pub-id></element-citation></ref><ref id="bib0019"><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Compton</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Elder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N.D.</given-names></name></person-group><article-title>Pregnancy and Postpartum Drug Overdose Deaths in the US Before and During the COVID-19 Pandemic</article-title><source>Jama Psychiat</source><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2023.4523</pub-id><pub-id pub-id-type="pmcid">PMC10918496</pub-id><pub-id pub-id-type="pmid">37991773</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Netherland</surname><given-names>J.</given-names></name></person-group><article-title>Is the Prescription Opioid Epidemic a White Problem?</article-title><source>Am. J. Public Health</source><volume>106</volume><issue>12</issue><year>2016</year><fpage>2127</fpage><lpage>2129</lpage><pub-id pub-id-type="pmid">27831792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2016.303483</pub-id><pub-id pub-id-type="pmcid">PMC5105018</pub-id></element-citation></ref><ref id="bib0021"><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S.</given-names></name></person-group><article-title>Two Tiers of Biomedicalization: methadone, Buprenorphine, and the Racial Politics of Addiction Treatment</article-title><source>Critical Perspectives on Addiction</source><year>2012</year></element-citation></ref><ref id="bib0022"><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Hollingsworth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruhm</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>K.</given-names></name></person-group><article-title>Macroeconomic conditions and opioid abuse</article-title><source>J. Health Econ.</source><volume>56</volume><year>2017</year><fpage>222</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">29128677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhealeco.2017.07.009</pub-id></element-citation></ref><ref id="bib0023"><mixed-citation publication-type="other" id="sbref0023">HRSA, 2020. Area Health Resources Files. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://data.hrsa.gov/topics/health-workforce/ahrf" id="interref0005">https://data.hrsa.gov/topics/health-workforce/ahrf</ext-link>.</mixed-citation></ref><ref id="bib0024"><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Tiako</surname><given-names>M.J.N.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>A.</given-names></name></person-group><article-title>Disparities in Addiction Treatment Learning from the Past to Forge an Equitable Future</article-title><source>Med Clin N Am</source><volume>106</volume><issue>1</issue><year>2022</year><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">34823733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2021.08.008</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>McCance-Katz</surname><given-names>E.F.</given-names></name></person-group><article-title>Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder</article-title><source>Addiction</source><volume>114</volume><issue>3</issue><year>2019</year><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">30194876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.14436</pub-id></element-citation></ref><ref id="bib0026"><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Christman</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Safferman</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Salzman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baston</surname><given-names>K.</given-names></name><name name-style="western"><surname>Haroz</surname><given-names>R.</given-names></name></person-group><article-title>Comparison between buprenorphine provider availability and opioid deaths among US counties</article-title><source>J. Subst. Abuse Treat.</source><volume>93</volume><year>2018</year><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">30126537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2018.07.008</pub-id></element-citation></ref><ref id="bib0027"><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Kaltenbach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Stine</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Arria</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>O'Grady</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Selby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>G.</given-names></name></person-group><article-title>Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure</article-title><source>N. Engl. J. Med.</source><volume>363</volume><issue>24</issue><year>2010</year><fpage>2320</fpage><lpage>2331</lpage><pub-id pub-id-type="pmid">21142534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1005359</pub-id><pub-id pub-id-type="pmcid">PMC3073631</pub-id></element-citation></ref><ref id="bib0028"><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Hell</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kaltenbach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Selby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Stine</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>O'Grady</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Arria</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>G.</given-names></name></person-group><article-title>Treatment of opioid-dependent pregnant women: clinical and research issues</article-title><source>J. Subst. Abuse Treat.</source><volume>35</volume><issue>3</issue><year>2008</year><fpage>245</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">18248941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2007.10.007</pub-id><pub-id pub-id-type="pmcid">PMC2633026</pub-id></element-citation></ref><ref id="bib0029"><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Kelty</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Cumming</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Preen</surname><given-names>D.B.</given-names></name></person-group><article-title>Contribution of pharmaceutical drugs of dependence to the incidence of neonatal abstinence syndrome in Western Australia between 2003 and 2018</article-title><source>Pharmacotherapy.</source><volume>42</volume><issue>5</issue><year>2022</year><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">35342965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2678</pub-id><pub-id pub-id-type="pmcid">PMC9541824</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Kocherlakota</surname><given-names>P.</given-names></name></person-group><article-title>Neonatal Abstinence Syndrome</article-title><source>Pediatrics.</source><volume>134</volume><issue>2</issue><year>2014</year><fpage>E547</fpage><lpage>E561</lpage><pub-id pub-id-type="pmid">25070299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2013-3524</pub-id></element-citation></ref><ref id="bib0031"><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Ku</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Druss</surname><given-names>B.G.</given-names></name></person-group><article-title>Associations Between Primary Care Provider Shortage Areas and County-Level COVID-19 Infection and Mortality Rates in the USA</article-title><source>J. Gen. Intern. Med.</source><volume>35</volume><issue>11</issue><year>2020</year><fpage>3404</fpage><lpage>3405</lpage><pub-id pub-id-type="pmid">32827110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-020-06130-4</pub-id><pub-id pub-id-type="pmcid">PMC7442285</pub-id></element-citation></ref><ref id="bib0032"><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Erikson</surname><given-names>C.E.</given-names></name></person-group><article-title>Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit</article-title><source><bold>JAMa</bold></source><volume>329</volume><issue>20</issue><year>2023</year><fpage>1792</fpage><lpage>1794</lpage><pub-id pub-id-type="pmid">37103912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.5038</pub-id><pub-id pub-id-type="pmcid">PMC10141275</pub-id></element-citation></ref><ref id="bib0033"><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Markus</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>D.</given-names></name></person-group><article-title>Mapping the Location of Health Centers in Relation to "Maternity Care Deserts</article-title><source>Med. Care</source><volume>59</volume><issue>10</issue><year>2021</year><fpage>S434</fpage><lpage>S440</lpage><pub-id pub-id-type="pmid">34524240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0000000000001611</pub-id><pub-id pub-id-type="pmcid">PMC8428862</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Mascarenhas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wachman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>I.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sarathy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>D.M.</given-names></name></person-group><article-title>Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome</article-title><source>Pediatrics.</source><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2023-062871</pub-id><pub-id pub-id-type="pmcid">PMC10827648</pub-id><pub-id pub-id-type="pmid">38178779</pub-id></element-citation></ref><ref id="bib0036"><mixed-citation publication-type="other" id="sbref0035">Missouri, 2020. Missouri Information for Community Assessment, accessed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://healthapps.dhss.mo.gov/MoPhims/QueryBuilder?qbc=PNM&amp;q=1&amp;m=1" id="interref0006">https://healthapps.dhss.mo.gov/MoPhims/QueryBuilder?qbc=PNM&amp;q=1&amp;m=1</ext-link>.</mixed-citation></ref><ref id="bib0037"><mixed-citation publication-type="other" id="sbref0036">MoD, 2022. March of Dimes Maternity Care Desert: data for Missouri. Published October 2022. (Accessed August 30, 2023 at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.marchofdimes.org/peristats/data?reg=99&amp;top=23&amp;stop=641&amp;lev=1&amp;slev=4&amp;obj=9&amp;sreg=29" id="interref0007">https://www.marchofdimes.org/peristats/data?reg=99&amp;top=23&amp;stop=641&amp;lev=1&amp;slev=4&amp;obj=9&amp;sreg=29</ext-link>).</mixed-citation></ref><ref id="bib0038"><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Nguemeni Tiako</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>D.M.</given-names></name></person-group><article-title>Prenatal Opioid Use Disorder Treatment-the Importance of Shared Decision-Making</article-title><source>JAMa Intern. Med.</source><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2023.6976</pub-id><pub-id pub-id-type="pmid">38252420</pub-id></element-citation></ref><ref id="bib0039"><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Novak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Feder</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: evidence from a national survey</article-title><source>J. Subst. Abuse Treat.</source><volume>98</volume><year>2019</year><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">30665603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2018.12.006</pub-id><pub-id pub-id-type="pmcid">PMC6350939</pub-id></element-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buntin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>W.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>W.</given-names></name></person-group><article-title>Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states</article-title><source>Subst. Abus.</source><volume>40</volume><issue>3</issue><year>2019</year><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">29949454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2018.1488336</pub-id><pub-id pub-id-type="pmcid">PMC9069995</pub-id></element-citation></ref><ref id="bib0041"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Faherty</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>B.</given-names></name></person-group><article-title>Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome</article-title><source>Jama-J Am Med Assoc</source><volume>321</volume><issue>4</issue><year>2019</year><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.20851</pub-id><pub-id pub-id-type="pmcid">PMC6439754</pub-id><pub-id pub-id-type="pmid">30694320</pub-id></element-citation></ref><ref id="bib0042"><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Faherty</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>B.D.</given-names></name></person-group><article-title>Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome</article-title><source>JAMa</source><volume>321</volume><issue>4</issue><year>2019</year><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">30694320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.20851</pub-id><pub-id pub-id-type="pmcid">PMC6439754</pub-id></element-citation></ref><ref id="bib0043"><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benneyworth</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krans</surname><given-names>E.</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.</given-names></name></person-group><article-title>Neonatal Abstinence Syndrome and Associated Health Care Expenditures United States, 2000-2009</article-title><source>Jama-J Am Med Assoc</source><volume>307</volume><issue>18</issue><year>2012</year><fpage>1934</fpage><lpage>1940</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.3951</pub-id><pub-id pub-id-type="pmid">22546608</pub-id></element-citation></ref><ref id="bib0044"><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Barfield</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Poindexter</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Committee On</surname><given-names>F.</given-names></name><name name-style="western"><surname>Newborn</surname><given-names>C.O.S.U.</given-names></name></person-group><article-title>Neonatal Opioid Withdrawal Syndrome</article-title><source>Pediatrics.</source><volume>146</volume><issue>5</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2020-029074</pub-id><pub-id pub-id-type="pmid">33106341</pub-id></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Piske</surname><given-names>M.</given-names></name><name name-style="western"><surname>Homayra</surname><given-names>F.</given-names></name><name name-style="western"><surname>Min</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marchand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mead</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Woolner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nosyk</surname><given-names>B.</given-names></name></person-group><article-title>Opioid Use Disorder and Perinatal Outcomes</article-title><source>Pediatrics.</source><volume>148</volume><issue>4</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2021-050279</pub-id><pub-id pub-id-type="pmid">34479983</pub-id></element-citation></ref><ref id="bib0046"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Pourat</surname><given-names>N.</given-names></name><name name-style="western"><surname>O'Masta</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sripipatana</surname><given-names>A.</given-names></name></person-group><article-title>Examining trends in substance use disorder capacity and service delivery by Health Resources and Services Administration-funded health centers: a time series regression analysis</article-title><source>PLoS. One</source><volume>15</volume><issue>11</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0242407</pub-id><pub-id pub-id-type="pmcid">PMC7703936</pub-id><pub-id pub-id-type="pmid">33253263</pub-id></element-citation></ref><ref id="bib0047"><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Rankin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Mosier-Mills</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hsiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wiznia</surname><given-names>D.H.</given-names></name></person-group><article-title>Secret shopper studies: an unorthodox design that measures inequities in healthcare access</article-title><source>Arch. Public Health</source><volume>80</volume><issue>1</issue><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13690-022-00979-z</pub-id><pub-id pub-id-type="pmcid">PMC9635177</pub-id><pub-id pub-id-type="pmid">36329541</pub-id></element-citation></ref><ref id="bib0048"><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Rees</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petrou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Botting</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>A.G.</given-names></name></person-group><article-title>Cost of neonatal abstinence syndrome: an economic analysis of English national data held in the National Neonatal Research Database</article-title><source>Arch Dis Child-Fetal</source><volume>106</volume><issue>5</issue><year>2021</year><fpage>F494</fpage><lpage>F500</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/archdischild-2020-319213</pub-id><pub-id pub-id-type="pmid">33627328</pub-id></element-citation></ref><ref id="bib0049"><mixed-citation publication-type="other" id="sbref0048">Roberts, T., Frederiksen, B., Saunders, H., Salganicoff, A., 2023. Opioid Use Disorder and Treatment Among Pregnant and Postpartum Medicaid Enrollees. Kaiser Family Foundation. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.kff.org/medicaid/issue-brief/opioid-use-disorder-and-treatment-among-pregnant-and-postpartum-medicaid-enrollees/" id="interref0008">https://www.kff.org/medicaid/issue-brief/opioid-use-disorder-and-treatment-among-pregnant-and-postpartum-medicaid-enrollees/</ext-link>. (Accessed January 10, 2024).</mixed-citation></ref><ref id="bib0050"><mixed-citation publication-type="other" id="sbref0049">Sciences, N.A.o., 2019. in: Mancher, M., Leshner, A.I. (Eds.), Medications for Opioid Use Disorder Save Lives. Washington (DC).<pub-id pub-id-type="pmid">30896911</pub-id></mixed-citation></ref><ref id="bib0051"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Silverstein</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Daniulaityte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>R.G.</given-names></name></person-group><article-title>Everything is not right anymore": buprenorphine experiences in an era of illicit fentanyl</article-title><source>Int. J. Drug Policy.</source><volume>74</volume><year>2019</year><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">31563098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2019.09.003</pub-id><pub-id pub-id-type="pmcid">PMC6914257</pub-id></element-citation></ref><ref id="bib0052"><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Strang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koob</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>B.D.L.</given-names></name><name name-style="western"><surname>Tyndall</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name></person-group><article-title>Opioid use disorder</article-title><source>Nat. Rev. Dis. Primers.</source><volume>6</volume><issue>1</issue><year>2020</year><fpage>3</fpage><pub-id pub-id-type="pmid">31919349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-019-0137-5</pub-id></element-citation></ref><ref id="bib0053"><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Stringfellow</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>M.S.</given-names></name></person-group><article-title>The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States</article-title><source>Addiction</source><volume>118</volume><issue>11</issue><year>2023</year><fpage>2215</fpage><lpage>2219</lpage><pub-id pub-id-type="pmid">37434347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.16291</pub-id></element-citation></ref><ref id="bib0054"><mixed-citation publication-type="other" id="sbref0053">UrbanInstitute, 2018. Neonatal Abstinence Syndrome and Maternal Access to Treatment for Opioid Use Disorder in California Counties: NAS Incidence and Driving Distance to Treatment for Pregnant Women. Accessed July 24, 2021, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.urban.org/sites/default/files/publication/98964/neonatal_abstinence_syndrome_and_maternal_access_to_treatment_for_opioid_use_disorder_in_california_counties_1.pdf" id="interref0009">https://www.urban.org/sites/default/files/publication/98964/neonatal_abstinence_syndrome_and_maternal_access_to_treatment_for_opioid_use_disorder_in_california_counties_1.pdf</ext-link>.</mixed-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Villapiano</surname><given-names>N.</given-names></name><name name-style="western"><surname>Winkelman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kozhimannil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name></person-group><article-title>Rural and Urban Differences in Neonatal Abstinence Syndrome and Maternal Opioid Use, 2004 to 2013</article-title><source>JAMa Pediatr.</source><volume>171</volume><issue>2</issue><year>2017</year><fpage>194</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">27942711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2016.3750</pub-id></element-citation></ref><ref id="bib0056"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Winkelman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Villapiano</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kozhimannil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name></person-group><article-title>Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid</article-title><source>Pediatrics.</source><volume>141</volume><issue>4</issue><year>2018</year><fpage>2004</fpage><lpage>2014</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2017-3520</pub-id><pub-id pub-id-type="pmcid">PMC5869343</pub-id><pub-id pub-id-type="pmid">29572288</pub-id></element-citation></ref><ref id="bib0057"><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Winograd</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Presnall</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stringfellow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Horn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rudder</surname><given-names>T.</given-names></name></person-group><article-title>The case for a medication first approach to the treatment of opioid use disorder</article-title><source>Am J Drug Alcohol Ab</source><volume>45</volume><issue>4</issue><year>2019</year><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00952990.2019.1605372</pub-id><pub-id pub-id-type="pmid">31084515</pub-id></element-citation></ref><ref id="bib0058"><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Work</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Muftu</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>K.D.L.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilens</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Greenfield</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>D.M.</given-names></name></person-group><article-title>Prescribed and Penalized: the Detrimental Impact of Mandated Reporting for Prenatal Utilization of Medication for Opioid Use Disorder</article-title><source>Matern Child Hlth J</source><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10995-023-03672-x</pub-id><pub-id pub-id-type="pmcid">PMC10229393</pub-id><pub-id pub-id-type="pmid">37253899</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="optKAlRxZ4af6"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>V.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Bazazi</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Grucza</surname><given-names>R.A.</given-names></name></person-group><article-title>Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: an analysis of insurance claims</article-title><source>Drug Alcohol Depend Rep</source><volume>9</volume><year>2023</year><fpage>100195</fpage><pub-id pub-id-type="pmid">38023343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadr.2023.100195</pub-id><pub-id pub-id-type="pmcid">PMC10630609</pub-id></element-citation></ref><ref id="bib0059"><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Bierut</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Grucza</surname><given-names>R.A.</given-names></name></person-group><article-title>Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant Compared With Nonpregnant People</article-title><source>Obstet. Gynecol.</source><volume>141</volume><issue>4</issue><year>2023</year><fpage>845</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">36897142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000005117</pub-id><pub-id pub-id-type="pmcid">PMC10201921</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bierut</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Grucza</surname><given-names>R.A.</given-names></name></person-group><article-title>Racial and Ethnic Disparities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-State Medicaid Claims in the USA (2011-2016)</article-title><source>J. Gen. Intern. Med.</source><volume>38</volume><issue>16</issue><year>2023</year><fpage>3499</fpage><lpage>3508</lpage><pub-id pub-id-type="pmid">37436568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-023-08306-0</pub-id><pub-id pub-id-type="pmcid">PMC10713957</pub-id></element-citation></ref></ref-list><sec id="sec0019" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0036a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><fn-group><fn id="sec0018" fn-type="supplementary-material"><p id="para0009a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.dadr.2024.100218" id="interref0001">doi:10.1016/j.dadr.2024.100218</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>